Versatile Amplification Method for Single-Molecule Detection in Liquid Biopsy

Informations projet

VerSiLiB

N° de convention de subvention: 101046217

DOI

10.3030/101046217

Projet clôturé

Date de signature de la CE 21 Mars 2022

Date de début 1 Avril 2022

Date de fin 31 Mars 2026

Financé au titre de

• The European Innovation Council (EIC)

Coût total

€ 2 994 244,99

Contribution de l’UE

€ 2 994 244,99

Coordonné par

TEKNOLOGIAN TUTKIMUSKESKUS VTT OY
Finland

Periodic Reporting for period 2 - VerSiLiB (Versatile Amplification Method for Single-Molecule Detection in Liquid Biopsy)

Période du rapport: 2023-04-01 au 2024-09-30

Résumé du contexte et des objectifs généraux du projet

Project aims to develop a proof-of-concept of a novel in-vitro diagnostic system that combines the analysis of DNA and protein biomarkers into one proteogenomic test. Project is the first step to enable fast and easy-to-use proteogenomic tests that will be widely applicable in the diagnosis of several significant diseases including viral outbreaks, cancers, and neuro-degenerative, immune and cardiovascular diseases. In the end of the project, the developed technology will be validated for real-life cancer management in a clinical setting.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Work during the first 2.5 years of the project has focused on:
• Defining system specifications
• Development of the sensor test chemistry for protein and DNA assay
• Design and implementation of the second version of the microfluidic chip
• Design and development of the integrated hardware prototype
• Conducting simulations and theoretical analyses
• Development of reference tests and standards of truths
• Collection of clinical samples

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Work to develop diagnostic system based on novel Affinity Mediated Transport amplification method has continued in close collaboration of the highly multi-disciplinary consortium combining expertise in molecular biology, chemistry, physical sciences, engineering, and medicine. During the 2.5 years of the project, the consortium has focused on finding solutions to the joint challenges with test chemistry and hardware design. Once the system is successfully developed and its foreseen advantages are demonstrated, it has potential to impact widely to the proteogenomic analyses in medical but also in other application fields utilizing molecular analysis.